TWI788343B - 治療用化合物 - Google Patents

治療用化合物 Download PDF

Info

Publication number
TWI788343B
TWI788343B TW107113171A TW107113171A TWI788343B TW I788343 B TWI788343 B TW I788343B TW 107113171 A TW107113171 A TW 107113171A TW 107113171 A TW107113171 A TW 107113171A TW I788343 B TWI788343 B TW I788343B
Authority
TW
Taiwan
Prior art keywords
methyl
pyrazol
oxo
pyridin
img
Prior art date
Application number
TW107113171A
Other languages
English (en)
Chinese (zh)
Other versions
TW201841900A (zh
Inventor
萊尼 崔羅斯
胡安曼努爾 貝坦科特
陶費吉 甘努尼
麥可布雷南 華勒斯
阿莫克 柏盧爾
Original Assignee
美商塞爾基因定量細胞研究公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商塞爾基因定量細胞研究公司 filed Critical 美商塞爾基因定量細胞研究公司
Publication of TW201841900A publication Critical patent/TW201841900A/zh
Application granted granted Critical
Publication of TWI788343B publication Critical patent/TWI788343B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW107113171A 2017-04-18 2018-04-18 治療用化合物 TWI788343B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762486894P 2017-04-18 2017-04-18
US62/486,894 2017-04-18
US201862657456P 2018-04-13 2018-04-13
US62/657,456 2018-04-13

Publications (2)

Publication Number Publication Date
TW201841900A TW201841900A (zh) 2018-12-01
TWI788343B true TWI788343B (zh) 2023-01-01

Family

ID=63791349

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107113171A TWI788343B (zh) 2017-04-18 2018-04-18 治療用化合物
TW111146299A TW202332436A (zh) 2017-04-18 2018-04-18 治療用化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111146299A TW202332436A (zh) 2017-04-18 2018-04-18 治療用化合物

Country Status (5)

Country Link
US (4) US10617680B2 (enExample)
EP (1) EP3612522A4 (enExample)
JP (2) JP2020516672A (enExample)
TW (2) TWI788343B (enExample)
WO (1) WO2018195155A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617680B2 (en) * 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
IL279734B2 (en) * 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
TW202304303A (zh) 2021-04-13 2023-02-01 美商富曼西公司 殺真菌之吡啶酮
JP2024523491A (ja) 2021-06-29 2024-06-28 タイ セラピューティクス リミテッド がんの治療に有用なピロロピリドン誘導体
WO2025010291A2 (en) * 2023-07-03 2025-01-09 The General Hospital Corporation Targeted epigenetic therapies for disorders of progranulin deficiency

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054434A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
US20130109652A1 (en) * 2004-09-17 2013-05-02 Addex Pharmaceuticals S.A. Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
WO2014055548A1 (en) * 2012-10-02 2014-04-10 Intermune, Inc. Anti-fibrotic pyridinones
WO2015058160A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
JPH11509835A (ja) 1995-05-19 1999-08-31 ジー．ディー．サール アンド カンパニー 炎症を治療するための置換オキサゾール
WO1997001551A1 (en) * 1995-06-26 1997-01-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds and pharmaceutical compositions
JP3760957B2 (ja) * 1996-03-05 2006-03-29 信越化学工業株式会社 新規スルホニウム塩及び化学増幅ポジ型レジスト材料
WO2001002400A1 (en) * 1999-07-02 2001-01-11 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
WO2002078625A2 (en) 2001-03-28 2002-10-10 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
CA2533626A1 (en) * 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
ATE455546T1 (de) * 2003-08-06 2010-02-15 Vertex Pharma Aminotriazol-verbindungen als proteinkinase- hemmer
EP1737841A1 (en) * 2004-04-01 2007-01-03 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
US7361654B2 (en) * 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JPWO2006137465A1 (ja) * 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
TW200745034A (en) * 2005-09-01 2007-12-16 Astellas Pharma Inc New compounds
WO2007040208A1 (ja) * 2005-10-03 2007-04-12 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
KR101352973B1 (ko) 2005-10-26 2014-01-22 삼성에스디아이 주식회사 연료전지용 탈황흡착제 및 이를 이용한 탈황방법
WO2007106349A2 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
JP5182088B2 (ja) * 2006-04-19 2013-04-10 アステラス製薬株式会社 アゾールカルボキサミド誘導体
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
TW200906825A (en) 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
WO2009028543A1 (ja) * 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
CN102131801B (zh) * 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
GB0919380D0 (en) * 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
CN102812022B (zh) * 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
WO2012020786A1 (ja) 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
US9481670B2 (en) 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
JP6130383B2 (ja) * 2011-09-30 2017-05-17 エンドゥ ファーマシューティカルズ，インコーポレイティド ピリジン誘導体
WO2013180183A1 (ja) 2012-05-30 2013-12-05 日本新薬株式会社 芳香族複素環誘導体及び医薬
HK1208681A1 (en) 2012-06-12 2016-03-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
JP2016512543A (ja) 2013-03-12 2016-04-28 アッヴィ・インコーポレイテッド ジヒドロ−ピロロピリジノンブロモドメイン阻害剤
US9670221B2 (en) 2013-03-14 2017-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Furopyridines as bromodomain inhibitors
ES2661012T3 (es) * 2013-03-28 2018-03-27 Takeda Pharmaceutical Company Limited Compuesto heterocíclico
RU2015147601A (ru) 2013-05-01 2017-06-05 Ф. Хоффманн-Ля Рош Аг С-связанные гетероциклоалкилзамещенные пиримидины и их применения
KR102394518B1 (ko) 2014-01-09 2022-05-06 오리온 코포레이션 브로모도메인 억제제로서의 비사이클릭 헤테로사이클릭 유도체
RU2692485C2 (ru) * 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
JP2017528486A (ja) * 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
EP3322409A4 (en) * 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
CA2992406A1 (en) * 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
WO2017026516A1 (ja) * 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
HK1255102A1 (zh) * 2015-09-21 2019-08-02 Plexxikon Inc. 杂环化合物及其应用
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
AU2017300336B2 (en) 2016-07-18 2021-03-11 National Institute Of Biological Sciences, Beijing Apoptosis inhibitors
US10617680B2 (en) 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
AR111479A1 (es) 2017-04-18 2019-07-17 Celgene Quanticel Res Inc Compuestos derivados de piridina y pirazol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130109652A1 (en) * 2004-09-17 2013-05-02 Addex Pharmaceuticals S.A. Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
US20090054434A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
WO2014055548A1 (en) * 2012-10-02 2014-04-10 Intermune, Inc. Anti-fibrotic pyridinones
WO2015058160A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors

Also Published As

Publication number Publication date
US11020380B2 (en) 2021-06-01
WO2018195155A1 (en) 2018-10-25
US11890275B2 (en) 2024-02-06
JP2020516672A (ja) 2020-06-11
US20210205284A1 (en) 2021-07-08
TW202332436A (zh) 2023-08-16
US20240293381A1 (en) 2024-09-05
EP3612522A1 (en) 2020-02-26
US20180296543A1 (en) 2018-10-18
US20200163946A1 (en) 2020-05-28
US10617680B2 (en) 2020-04-14
JP2023088901A (ja) 2023-06-27
EP3612522A4 (en) 2021-07-07
TW201841900A (zh) 2018-12-01

Similar Documents

Publication Publication Date Title
US11884680B2 (en) Bromodomain inhibitors
US11890275B2 (en) Therapeutic compounds
EP2049515B1 (en) Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis
US10336697B2 (en) Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors
TW201739744A (zh) 治療用化合物
US20240247014A1 (en) Modulators of tnf-alpha activity
JP2010505957A (ja) 糖尿病に対して使用されるｎ−アリールピラゾール化合物
KR20130062951A (ko) 키누레닌 생성 억제 작용을 갖는 함질소 복소환 화합물
KR20130130030A (ko) Vps34 억제제로서의 비-헤테로아릴 화합물
TW202041498A (zh) 抑制ｐｇｅ２／ｅｐ４信號傳導的化合物、其製備方法及其在醫藥上的應用
CN113272297B (zh) 作为h4拮抗剂化合物的吡唑衍生物
CN121311471A (zh) 异喹啉酮衍生物和4h-喹嗪酮衍生物以及其用于治疗疾病的药物组合物
WO2022213980A1 (zh) Tyk2抑制剂及其用途
KR20210022646A (ko) 시아노트리아졸 화합물 및 이의 용도
US12521368B2 (en) Modulators of TNF-alpha activity
JP2025506446A (ja) 特定の化学物質、組成物、および方法
HK1131134B (en) Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees